ClinicalTrials.gg
TerminatedNCT06961266Updated Apr 6, 2026

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

A Phase 1 interventional study of JZP441 and Matching Placebo in Narcolepsy, sponsored by Jazz Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Jazz Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated based on a business decision by the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
15th of 15
6 · median 120
Started
2025
the only one that year
Phase 1
Only one
of the 18
Registered
17th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1, and was the 17th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

Narcolepsy is a sleep disorder in which patients are not able to maintain wakefulness or require treatment to maintain wakefulness during the daytime. Narcolepsy is a lifelong neurologic disease for which no cure has been clinically available. JZP441 is currently being developed for the treatment of narcolepsy type 1 (NT1). This study will assess the safety of efficacy of JZP441 in adult patients with NT1.

Read the detailed description

This Phase 1b, randomized, double-blind, sponsor-unblinded, placebo-controlled 4-way crossover study will evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of a range of JZP441 doses in participants with NT1. Changes in daytime sleepiness will be assessed via objective (MWT) and subjective (KSS, VAS for sleepiness) efficacy measures.

03

Conditions studied

  • Narcolepsy

Browse trials for

Keywords

  • Narcolepsy Type 1
  • JZP441
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Is 18 to 64 years of age inclusive at the time of signing the .
  2. Has a physician diagnosis of NT1 according to ICSD-3-TR criteria
  3. Has an average sleep latency of less than 15 minutes, as documented by the mean of the first 4 trials of the Baseline MWT, as determined by central assessment.
  4. Has a minimum body weight of 50 kg for men and 45 kg for women and a within the range 18.0 to 35.0 kg/m\^2 (inclusive).
  5. Participant agrees to the following based on sex assigned at birth.

    1. Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 90 days after the last dose of study intervention:

      • Refrain from donating sperm
      • Use /barrier as specified in the protocol
    2. Female participants are eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

      • Is a woman of non- (WONCBP) OR
      • Is a WOCBP and using a contraceptive method that is highly effective during the study intervention period and until completion of the Safety Follow-up Period.
      • Male partners of WOCBP are required to use barrier protection, (eg, condoms) during the study intervention period and over the 90-day period after the last dose of study intervention.

        • A WOCBP must have a negative highly sensitive pregnancy test at screening and at check-in on Day -1 of each Treatment Visit, before the first dose of study intervention is administered.
      • If a urine test cannot be confirmed as negative, a serum pregnancy test is required.
  6. Is capable of giving signed informed consent

Participants are excluded from the study if any of the following criteria apply:

  1. Any other medical, behavioral, or psychiatric disorder other than NT1 that is associated with EDS.
  2. History or presence of gastrointestinal (including gastric bypass surgery within the past 10 years), hepatic disease, untreated thyroid disease, or any other condition that may interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Presence of severe renal impairment, end-stage renal disease or BSA-adjusted calculated \<60 mL/min.
  4. Presence of cardiodynamic abnormalities defined as triplicate 12-lead
  5. History or evidence of any of the following: myocardial infarction, cardiac surgery revascularization, unstable angina, cerebrovascular accident or stroke or , pacemaker, atrial fibrillation, flutter, syncope in the past 2 years from a cardiac etiology or unexplained syncope or non-sustained or sustained VT. Angina pectoris greater than Class 1, CHF greater than Class 1, personal or family history of the Long Syndrome, Brugada syndrome, Wolff-Parkinson-White syndrome, any history of heart block, family history of sudden death.
  6. Structural or functional heart abnormalities as determined by an echocardiogram performed within 6 months prior to screening, including \<45%; moderate or greater aortic or mitral stenosis or regurgitation.
  7. Presence or history of uncontrolled hypertension, systolic BP of at least 140 mmHg or diastolic BP of at least 90 mmHg (at Screening Visit, Baseline Visit, or prior to randomization).
  8. Laboratory values (chemistry, hematology, and urinalysis) outside the laboratory reference range considered to be clinically significant by the investigator.
  9. History of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to item 4 or item 5 on the C-SSRS (within the past 6 months).
  10. Current major depressive episode or presence of uncontrolled anxiety disorder according to criteria. Participants with stable treated depression and/or anxiety are allowed.
  11. Current or history of psychotic or bipolar disorders, or any first degree relative with a history of schizophrenia-spectrum disorder or bipolar I disorder.
  12. History (within the past year at screening) or presence of substance use disorder or alcohol use disorder per DSM-5 definition, known drug dependence, or seeking treatment for alcohol or substance use related disorder.
  13. History of seizure disorder or a physical condition that would increase seizure risk.
  14. History of ischemic event or a condition that elevates the participant's risk for an ischemic event
  15. Evidence of untreated or inadequately treated sleep-disordered breathing
  16. Concomitant or recent (within 5 half-lives) use of drugs that affect QT or QRS intervals, including sodium channel blockers.
  17. Use of any medications that could affect the evaluation of EDS within a time period prior to the Baseline Visit corresponding to at least 5 half-lives of the drug(s) or planned use during the study.
  18. Concomitant use of XYWAV, high sodium oxybate, or pitolisant. Other medications used for treatment of cataplexy (eg, antidepressants) are allowed.
  19. Participation in another clinical study of an drug (other than JZP441) or medical device within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention and throughout the duration of the study.
  20. Habitual bedtime later than 1:00 AM over the last 6 months, per self-report.
  21. Occupation requiring nighttime shift work or variable shift work.
  22. Travel across 3 or more time zones within 1 week of Baseline Visit or planned through duration of treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    JZP441 Dose Level 1

    Participants with narcolepsy type 1 who are randomized to receive JZP441.

    Drug: JZP441

  • Experimental
    JZP441 Dose Level 2

    Participants with narcolepsy type 1 who are randomized to receive JZP441.

    Drug: JZP441

  • Experimental
    JZP441 Dose Level 3

    Participants with narcolepsy type 1 who are randomized to receive JZP441.

    Drug: JZP441

  • Placebo comparator
    Placebo

    Participants with narcolepsy type 1 who are randomized to receive matching placebo.

    Drug: Matching Placebo

Interventions

  • DrugJZP441

    Administered orally

  • DrugMatching Placebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Mean sleep latency of the first 4 sessions of the Maintenance of Wakefulness Test

    The MWT is the standard objective measure of an individual's ability to remain awake during the daytime in a darkened quiet environment and is commonly used to assess response to treatment. The MWT will be used to compare the pharmacodynamic response of JZP441 versus placebo. Sleep latency will be reported in minutes.

    Time frame: 1, 3, 5, and 7 hours after the first dose of study intervention

Secondary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events

    A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) that started, or worsened in severity or seriousness, following a dose of study intervention.

    Time frame: Baseline up to Week 11

  2. Pharmacokinetic Parameter Maximum Plasma Concentration

    Time frame: Day 1 (predose), 2, 4, 6, 8, 10, and 12 hours post first dose; Day 2 (24 hours) post first dose.

  3. Pharmacokinetic Parameter Time to Maximum Plasma Concentration

    Time frame: Day 1 (predose), 2, 4, 6, 8, 10, and 12 hours post first dose; Day 2 (24 hours) post first dose.

  4. Pharmacokinetic Parameter Area Under the Plasma Concentration Curve

    Time frame: Day 1 (predose), 2, 4, 6, 8, 10, and 12 hours post first dose; Day 2 (24 hours) post first dose.

  5. Mean Score of the First 4 assessments of Karolinska Sleepiness Scale

    The Karolinska Sleepiness Scale (KSS) is a single-item, 9-point, self-administered questionnaire that measures a participant's subjective level of sleepiness (from "extremely alert" to "extremely sleepy, can't keep awake"). Scores generally decrease with longer periods of wakefulness, indicating that lower scores correlate with better outcomes.

    Time frame: 1, 3, 5, 7, 9 and 11 hours after first dose

  6. Mean VAS Score For Sleepiness

    The self-reported VAS measure of sleepiness in the current study will be a retrospective measure of how sleepy the participant felt throughout the day, with anchors at each end of the line labeled as "0=not at all sleepy" to "100=very sleepy." Higher VAS scores indicate worse outcome.

    Time frame: 1, 3, 5, 7, 9 and 11 hours after first dose

07

Study locations

4 sites
  • Clinical Trial Site
    Atlanta, Georgia 30328, United States
  • Clinical Trial Site
    Cincinnati, Ohio 45245, United States
  • Clinical Trial Site
    Columbia, South Carolina 29201, United States
  • Clinical Trial Site
    Austin, Texas 78731, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jan 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 7, 2025
StartActual
May 13, 2025
Primary completionActual
Jan 29, 2026
CompletionActual
Jan 29, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961266
Collaborators
Jazz Pharmaceuticals Ireland Limited
Responsible party
Sponsor
First posted
May 7, 2025
Start date
May 13, 2025
Primary completion
Jan 29, 2026
Completion
Jan 29, 2026
Last update
Apr 6, 2026

Study contacts

Global Medical Lead
study director · Jazz Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JZP441

Start the discussion